In 14q32 sits IgH, and IgL in 22q11. The translocation t(1;14 or 22)(q21;q32 or q11) is heterogeneous, since different cases have shown different genes in 1q21 deregulated by the translocation:
- BCL9 (Willis et al., 1998). BCL9 binds to CTNNB1 (beta-catenin) and is required for Wnt signal transduction (Kramps et al., 2002). BCL9 starts at 145479806 and ends at 145564639 bp from pter.
- MUC1 (Dyomin et al., 2000; the same case was independantly reported in Gilles et al., 2000). MUC1 is a membrane bound mucin expressed on the surface of epithelial cells to in protect epithelia (Carson, 2008). MUC1 starts at 153424924 and ends at 153429324 bp from pter.
- FCRL4 and/or FCRL5 (Hatzivassiliou et al., 2001; Sonoki et al., 2004). FCRL4 is a cell surface receptor related to the Fc receptor, inhibitory receptor superfamily, and cell adhesion molecule (CAM) families (Falini et al., 2003). FCRL4 starts at 155810163 and ends at 155834494 bp from pter.
- FCGR2B (Callanan et al., 2000; Chen et al., 2001). FCGR2B is a Low affinity IgG Fc receptor (Callanan and Leroux, 2002). FCGR2B starts at 159899564 and ends at 159914575 bp from pter.

As a matter of fact, these translocations span 1q21 to 1q23. Also, many other genes of interest are in the area delimited by BCL9 and FCGR2B (see http://atlasgeneticsoncology.org/Indexbychrom/idxa_1.html "Ordered by Location").
From the very short sample of cases for each partner gene, it is impossible to delineate different entities with different epidemiologies and prognoses. They are therefore needed, for clinical goals.